Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan

Angelo Maria Patti, Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, Niki Katsiki, Khalid Al-Rasadi, Manfredi Rizzo, Manfredi Rizzo

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids, lipoproteins, blood pressure, glucose, and insulin levels and their anti-inflammatory and anti-oxidant effects are documented. However, larger, prospective clinical trials are required to confirm such benefits. Such treatments may be recommended when lipid-lowering drugs are neither indicated nor tolerated as well as in order to achieve therapeutic targets and/or overcome residual CV risk.
Original languageEnglish
Pages (from-to)416-421
Number of pages6
JournalAngiology
Volume66
Publication statusPublished - 2015

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan'. Together they form a unique fingerprint.

Cite this